Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by AMAG Pharmaceuticals (formerly known as Lumara Pharmaceutical)
Lobbying Relationship
Bills mentioned
S.959: Pharmaceutical Quality, Security, and Accountability Act
Sponsor: Tom Harkin (D-Iowa)
H.R.3204: Drug Quality and Security Act
Sponsor: Fred Upton (R-Mich.)
H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013
Sponsor: Robert E. Latta (R-Ohio)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Jennifer Bell | Policy Advisor, Senate Finance Committee; LA, Sen. Thune Health Policy Advisor, Sen. Finance Committee Legislative Assistant, Rep. John Thune (R-SD) |
| Michaela Sims | Counsel, Sen. Ben Nelson; LD and Counsel, Sen. Kerrey Legislative Counsel, Sen. Ben Nelson (D-NE) Legislative Director and Counsel, Sen. Bob Kerrey (D-NE) Legislative Director, Sen. Bob Kerrey Legislative Counsel, Sen. Bob Kerrey Legislative Counsel, Sen. Ben Nelson (D-NE) |
| Adam Etzion | n/a |
| Jennifer Higgins | n/a |
| Katie Zirkelbach | n/a |
| Michelle Nawar | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate